^
    Back
    Association details:
    Biomarker:ERBB4 mutation
    Cancer:Melanoma
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Lapatinib in Stage IV Melanoma With ERBB4 Mutations

    Excerpt:
    ......
    Trial ID:
    NCT01264081
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nat Genet
    Title:

    Analysis of the Tyrosine Kinome in Melanoma Reveals Recurrent Mutations in ERBB4

    Excerpt:
    Exposure of melanoma cells to lapatinib resulted in reduced cell proliferation to a greater extent in cells containing endogenous ERBB4 mutations than in cells containing endogenous WT ERBB4 (Figure 5A). An IC50 calculation revealed that melanoma cells harboring ERBB4 mutations were 10–250 fold more sensitive to lapatinib than cells with WT receptor (Figure 5B) and treatment with lapatinib inhibited receptor autophosphorylation in a dose-dependent manner.
    DOI:
    10.1038/ng.438